iRhythm Technologies Inc. (IRTC)
undefined
undefined%
At close: undefined
86.43
-0.13%
After-hours Dec 13, 2024, 04:39 PM EST

Company Description

iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States.

It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias.

The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data.

It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products.

The company was incorporated in 2006 and is headquartered in San Francisco, California.

iRhythm Technologies Inc.
iRhythm Technologies Inc. logo
Country United States
IPO Date Oct 20, 2016
Industry Medical - Devices
Sector Healthcare
Employees 2,000
CEO Quentin S. Blackford

Contact Details

Address:
699 8th Street
San Francisco, California
United States
Website https://www.irhythmtech.com

Stock Details

Ticker Symbol IRTC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001388658
CUSIP Number 450056106
ISIN Number US4500561067
Employer ID 20-8149544
SIC Code 3841

Key Executives

Name Position
Quentin S. Blackford President, Chief Executive Officer & Director
Chad M. Patterson Chief Commercial Officer
Daniel G. Wilson Executive Vice President of Corporate Development & Investor Relations
Dr. Minang P. Turakhia M.D., M.S. Chief Medical & Scientific Officer and Executive Vice President of Product Innovation
Marc Rosenbaum Senior Vice President of Finance & Chief Accounting Officer
Mervin Smith Executive Vice President of Business Operations
Patrick Michael Murphy J.D. Chief Business & Legal Officer
Stephanie Zhadkevich Director of Investor Relations
Sumi Shrishrimal Executive Vice President & Chief Risk Officer

Latest SEC Filings

Date Type Title
Dec 03, 2024 4 Filing
Nov 14, 2024 8-K Current Report
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 07, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 05, 2024 4 Filing
Nov 05, 2024 4 Filing
Oct 30, 2024 10-Q Quarterly Report
Oct 30, 2024 8-K Current Report
Oct 10, 2024 8-K Current Report